Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bosentan in inoperable chronic thromboembolic pulmonary hypertension
2005-001965-33Phase 3Completed
- Sponsor
- Actelion Pharmaceuticals Ltd
- Start
- Aug 2005
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in chronic thromboembolic pulmonary hypertension (CTEPH) and pulmonary embolism (PE) comparing Bosentan with Placebo (2 arms). Primary endpoints: Co-primary endpoint 1 and Co-primary endpoint 2. Started Aug 2005; status: completed.
02
Drugs
bosentan
03
Conditions
chronic thromboembolic pulmonary hypertension (CTEPH)pulmonary embolism (PE)
Beyond the preview
Go deeper on 2005-001965-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-001965-33.